AANS Neurosurgeon | Volume 26, Number 1, 2017


Discovery May Lead to a Treatment to Slow Parkinson's Disease

Bookmark and Share

Interaction between a mutant gene and alpha synuclein leads to hallmark Parkinson’s pathologies¬†

In this study, researchers were able to see that LRRK2, a mutant kinase enzyme that is the most common genetic cause for Parkinson’s disease, can cause the buildup of inclusions in neurons. These inclusions are one of the main pathologies seen in patients with Parkinson’s disease. New drugs that are currently being developed for clinical use would inhibit the buildup of inclusions stopping the aggregated alpha synuclein protein which would slow the progression of the disease. To read more, click here.


2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.

Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany

Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.

Comments are closed.